237
Views
9
CrossRef citations to date
0
Altmetric
Original Articles

A cobalt(II) complex with anionic and neutral N-donor ligands: synthesis, crystal structure, and application as a heterogeneous catalyst for olefin epoxidation with tert-BuOOH

, &
Pages 980-992 | Received 31 Aug 2014, Accepted 30 Dec 2014, Published online: 06 Feb 2015
 

Abstract

A cobalt(II) complex containing deprotonated mefenamic acid (Hmef) and imidazole (HIm), [Co(mef)2(HIm)2(CH3OH)2], has been synthesized and characterized by spectroscopic techniques (UV–vis, IR, and EPR), elemental analysis, and single-crystal X-ray diffraction analysis. The structure has distorted octahedral geometry around cobalt. The mefenamate is a monodentate ligand coordinated to the Co(II) through a carboxylate oxygen. This complex was tested as a catalyst for epoxidation of alkenes with tert-BuOOH in 1,2-dichloroethane solution. This catalyst was effective in epoxidation of various alkenes including non-activated terminal alkenes. The effects of solvent, oxidant, and temperature on the epoxidation of cyclohexene were investigated. In all cases, high yields of epoxidized alkenes were obtained.

Acknowledgements

We are grateful for the financial support from the Department of Chemistry, Isfahan University of Technology (IUT). Also, the authors would like to thank the Raha Pharmacological Company for providing us with the required mefenamic acid.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.